Literature DB >> 11061852

Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results.

D H Culver1, M J Alter, R J Mullan, H S Margolis.   

Abstract

BACKGROUND: As part of a nationwide program to identify persons at increased risk for HCV infection, persons who received blood from donors who later tested positive for anti-HCV are being directly notified. STUDY DESIGN AND METHODS: In December 1999, all 198 blood collection establishments (BCEs) and 5442 hospital transfusion services (TSs) in the United States were surveyed by mailed questionnaire to evaluate their progress in carrying out this notification.
RESULTS: Eighty-one percent of the BCEs and 64 percent of the TSs responded. After correcting for nonresponse, an estimated 98,484 components at potential risk for transmitting HCV, according to previous testing of multiantigen-screened donors, were identified nationwide, of which 85 percent had been transfused to recipients. Lookback for these recipients was completed for 80 percent, of whom 69 percent had died. Of those living, 78 percent were successfully notified. An estimated 49.5 percent of those notified were tested; 18.9 percent of those tested were anti-HCV positive, and 32 percent of that group knew they were positive before notification. On the basis of an 85.5 percent reported completion rate for component notifications back through 1988, an estimated 1520 persons will have been newly identified as anti-HCV-positive when lookback related to multiantigen screening of donors is completed.
CONCLUSION: Targeted lookback related to previous multiantigen screening of donors will identify <1 percent of the estimated 300,000 HCV-positive persons in the United States who may have acquired their infection via blood transfusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061852     DOI: 10.1046/j.1537-2995.2000.40101176.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

1.  The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Authors:  David B Rein; Bryce D Smith; John S Wittenborn; Sarah B Lesesne; Laura D Wagner; Douglas W Roblin; Nita Patel; John W Ward; Cindy M Weinbaum
Journal:  Ann Intern Med       Date:  2011-11-04       Impact factor: 25.391

2.  Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.

Authors:  C Bradley Hare; Jacqueline J Loveland; Alice Chu; Jonathan A Morris; Vincent Gotz; Winslow Klaskala
Journal:  Curr Ther Res Clin Exp       Date:  2005-09

3.  Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.

Authors:  W N Southern; M-L Drainoni; B D Smith; C L Christiansen; D McKee; A L Gifford; C M Weinbaum; D Thompson; E Koppelman; S Maher; A H Litwin
Journal:  J Viral Hepat       Date:  2010-05-20       Impact factor: 3.728

4.  The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Authors:  David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward
Journal:  Clin Infect Dis       Date:  2015-03-16       Impact factor: 9.079

5.  Hepatitis C: the end of the beginning and possibly the beginning of the end.

Authors:  Harvey J Alter; T Jake Liang
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

6.  Physician nonadherence with a hepatitis C screening program.

Authors:  William N Southern; Mari-Lynn Drainoni; Bryce D Smith; Elisa Koppelman; M Diane McKee; Cindy L Christiansen; Allen L Gifford; Cindy M Weinbaum; Alain H Litwin
Journal:  Qual Manag Health Care       Date:  2014 Jan-Mar       Impact factor: 0.926

7.  The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots.

Authors:  Boris Kauhl; Jeanne Heil; Christian J P A Hoebe; Jürgen Schweikart; Thomas Krafft; Nicole H T M Dukers-Muijrers
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

8.  Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016.

Authors:  Leisha D Nolen; Courtney Gustin; Sara Seeman; Neil Murphy; Sarah Truitt; Sarah Schillie; Michael G Bruce; Dana Bruden; James Tiesinga; Brian McMahon
Journal:  Can J Gastroenterol Hepatol       Date:  2019-06-02

Review 9.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

10.  Transmission of viral hepatitis through blood transfusion in Sweden, 1968 to 2012.

Authors:  Viktor Dahl; Ammar Majeed; Agneta Wikman; Rut Norda; Gustaf Edgren
Journal:  Euro Surveill       Date:  2020-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.